Integrum is glad to announce the approval of our prosthetic subcontractor by the FDA. The approval process was completed after a successful FDA inspection. This inspection included the PMA assessment in the scope.
This approval secures scalable deliveries to both the US and other markets and is an important milestone in the PMA application process.
The OPRA™ Axor™ II attaches to the Abutment end that is outside of the skin and acts as a safety connection between the Abutment and the prosthesis. It is designed to prevent damage to the bone-anchored Fixture and the skeleton. If overload occurs, the Axor™ II acts similar to a ski-binding and “releases” the prosthesis to protect the implant and the skeleton from damage.
Integrum is glad to continue providing the highest quality products that meets the requirements of safety for our patients.
The information in this press release is information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 13:45 CET on April 1st, 2020.
Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser is the Company´s Certified Adviser.
For further information contact
María López, CEO. Mobile: +46 708 46 10 69, Email: email@example.com
Erik Penser Bank AB, Certified Adviser can be reached at +46 8 463 8000 or firstname.lastname@example.org